New England Journal of Medicine· 2019Q1· Clinical trial

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Vlado Perkovic, Meg Jardine, Bruce Neal, Séverine Bompoint et al.

6,036citations
Q1SCImago
2019year

Short summary

In patients with type 2 diabetes and kidney disease, canagliflozin significantly reduced the risk of kidney failure and major cardiovascular events by 30% compared to placebo over a median follow-up of 2.62 years.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Endocrinology, Diabetes and Metabolism

Endocrinology, Diabetes and MetabolismMedicine